Related Experiment Video
Updated: Jun 1, 2025
08:36
In Vitro Assay to Study Tumor-macrophage Interaction
Published on: August 1, 2019
7.5K
Macrophage Infiltration and ITGB2 Expression in ESCC: A Novel Correlation
Tao Huang1, Longqian Wei1, Huafu Zhou1
1Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China.
Cancer Medicine
|January 18, 2025
Summary
Macrophage infiltration in esophageal squamous cell carcinoma (ESCC) correlates with ITGB2 expression, suggesting ITGB2 as a target for novel immunotherapies. Targeting ITGB2 in M1 macrophages offers a promising new strategy for ESCC treatment.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Esophageal squamous cell carcinoma (ESCC) is a leading cause of cancer death globally.
- Current immunotherapies show limited efficacy in ESCC, necessitating new therapeutic targets.
- Understanding tumor immunity in ESCC is crucial for developing effective treatments.
Purpose of the Study:
- To identify key genes involved in immune infiltration in ESCC.
- To investigate the relationship between these genes, immune cell development, and immunotherapy potential.
- To explore ITGB2 as a potential biomarker and therapeutic target in ESCC.
Main Methods:
- Integration of high-throughput sequencing, gene chip, and single-cell sequencing data.
- Bioinformatics analysis and experimental validation.
- Analysis of gene expression, immune cell infiltration, and miRNA interactions.
Main Results:
- A positive correlation was found between macrophage infiltration and ITGB2 expression in ESCC.
- ITGB2 is overexpressed in ESCC and linked to tumor-promoting macrophage polarization.
- ITGB2 expression in macrophages increases with ESCC progression, indicating its potential as a therapeutic target and biomarker for immunotherapy response.
- Three miRNAs associated with ITGB2 expression were identified.
Conclusions:
- Macrophage infiltration and ITGB2 expression are closely linked in ESCC, highlighting ITGB2's immunotherapy potential.
- A novel strategy involving ITGB2-knockout M1 macrophages is proposed for ESCC immunotherapy.
- This research opens new avenues for developing targeted immunotherapies for esophageal squamous cell carcinoma.
